Through our expertise in TLR biology we are developing compounds that stimulate multiple innate mechanisms of tumor killing and generate immune memory to antigens expressed by tumor cells. Our TLR agonists were specifically designed for cancer to stimulate multiple pathways of tumor killing through type 1 interferon induction and highly efficient stimulation of antigen presenting functions of plasmacytoid dendritic cells (PDC).
PDC are widely observed in tumors and are key components to the innate immune system. PDC express intracellular TLR9 which, upon stimulation, produces large amounts of type 1 interferon. This innate immune response is the backbone of our approach to fighting cancer using our proprietary TLR agonists.